Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinosarcoma × pamiparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gynecologic 1

Conditions

Ovarian Neoplasms 4 Stomach Neoplasms 1 Rare Tumour 1 Neoplasms 1 Neoadjuvant Therapy 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 Locally Advanced Prostate Cancer 1 Limited Stage Small Cell Lung Cancer 1 Hereditary leiomyomatosis and renal cell cancer 1 HER2-negative Breast Cancer 1 Carcinosarcoma 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Biliary Tract Neoplasms 1

Interventions

Nivolumab 5 Paclitaxel 3 olaparib 2 Specimen Handling 2 Magnetic Resonance Spectroscopy 2 rucaparib 1 pazopanib 1 pamiparib 1 durvalumab 1 ceralasertib 1 cediranib 1 cabozantinib 1 apatinib 1 Trabectedin 1 Ipilimumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 CTLA-4 Antigen 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03933761 2021-08-10

PRECISE

Australia New Zealand Gynaecological Oncology Group

Phase 2 Withdrawn

GynecologicSarcoma

Carcinosarcoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡